A standalone business restructuring involving the integration of Toyama Chemical Co., Ltd. and FUJIFILM RI Pharma Co., Ltd. to accelerate the development of new drugs, including diagnostic and therapeutic agents based on small-molecule pharmaceuticals and radiopharmaceuticals. The restructuring theme covers the subsequent transfer of the radiopharmaceutical business after the integration.